Summarized by Masters of Longevity from Longevity Technology.
Five-year clinical and real-world lecanemab findings were presented for early Alzheimer’s patients.
Key Takeaways
- Eisai reported five-year outcomes for lecanemab treatment.
- Real-world studies showed safety, ARIA rates, and administration findings.
- Biomarker analyses assessed CSF proteins and durability after stopping.
